方法：糖尿病性视神经病变患者67例115眼，根据是否需要激光视网膜光凝治疗分为两组，每组随机分为常规治疗组和M-NGF治疗组，均给予常规治疗，M-NGF治疗组加用M-NGF，疗程3wk。治疗后随访2mo，比较各组患者治疗后视力、视野恢复情况，并观察M-NGF治疗的安全性。

结果：在不需要激光视网膜光凝组，常规治疗和M-NGF治疗的总有效率分别为71.4%和94.7%，后者总有效率高于前者(P<0.05)； 在需要激光视网膜光凝组，常规治疗和M-NGF治疗的总有效率分别为73.0%和93.3%，后者总有效率高于前者(P<0.05)； 在激光组和非激光组，治疗效果无明显统计学差异(P>0.05)。除个别患者注射部位出现局部疼痛、红肿硬结外，未见其它不良反应。

结论：M-NGF治疗DON安全、有效，值得临床推广应用。

METHODS: All 67 cases(115 eyes)with DON were randomly divided into two groups according to the need of photocoagulation or not, and each group was randomly divided into normal treatment group and M-NGF treatment group. Patients in normal treatment group were treated by conventional way and those in M-NGF treatment group were treated with M-NGF plus conventional treatment for 3 weeks. Two months later, the vision and visual field of different groups were inspected and the safety was evaluated.

RESULTS: The effective rate was 71.4% in normal treatment group and 94.7% in M-NGF treatment group(P<0.05)in non-photocoagulation group, and 73.0% in normal treatment group and 93.3% in M-NGF treatment group(P<0.05)in photocoagulation group. The general effective rate of later was higher than the former(P<0.05), while the treatment effect had no significant statistical difference(P>0.05). Apart from local injection pain and swelling scleroma in several patients, other side effects were not found.

CONCLUSION: M-NGF is an effective and safe way to treat DON, which is worth widely applying in clinical practice.